Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Recruiting
Phase 1
Interventional Study
Demyelinating Disorders
MCI
Alzheimer's Disease (AD)
MS (Multiple Sclerosis)
SCI - Spinal Cord Injury
Spinal Radiculopathy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 – 90
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 105 (estimated)
- Sponsor
- Yale University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion:
1. Male and Female subjects must be ≥18 and \<90 years of age;
2. Able to understand and provide informed consent prior to study procedures
3. Must be in good health
Exclusion:
1. Less than 18 years of age;
2. Pregnant or breastfeeding;
3. Any significant systemic illness or unstable m…
Contacts